Back to Feed
ClinicalTrials.gov|Clinical Trial
Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Abstract
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors. Phase: NA Status: RECRUITING Conditions: HER2-positive Advanced Malignant Solid Tumors Interventions: Anti-HER2 CAR-T cells
Keywords
HER2-positive Advanced Malignant Solid Tumors